HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Peritoneal Fibrosis

Subscribe to New Research on Peritoneal Fibrosis

Disorder characterized by a wide range of structural changes in PERITONEUM, resulting from fibrogenic or inflammatory processes. Peritoneal fibrosis is a common complication in patients receiving PERITONEAL DIALYSIS and contributes to its gradual decrease in efficiency.

Also Known As:

Encapsulating Peritoneal Scleroses; Fibroses, Peritoneal; Fibrosing Syndrome, Peritoneal; Fibrosing Syndromes, Peritoneal; Fibrosis, Peritoneal; Peritoneal Fibroses; Peritoneal Fibrosing Syndromes; Peritoneal Scleroses; Peritoneal Scleroses, Encapsulating; Peritoneal Sclerosis, Encapsulating; Scleroses, Encapsulating Peritoneal; Scleroses, Peritoneal; Sclerosis, Encapsulating Peritoneal; Sclerosis, Peritoneal; Syndrome, Peritoneal Fibrosing; Syndromes, Peritoneal Fibrosing; Encapsulating Peritoneal Sclerosis; Peritoneal Fibrosing Syndrome; Peritoneal Sclerosis

Networked: 639 relevant articles (29 outcomes, 72 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Peritoneal Fibrosis
2.	Peritonitis
3.	Inflammation
4.	Fibrosis (Cirrhosis)
5.	Uremia

Experts

1.	Krediet, Raymond T: 20 articles (05/2015 - 05/2004)
2.	Kawanishi, Hideki: 20 articles (01/2015 - 01/2002)
3.	Kohno, Shigeru: 15 articles (05/2015 - 01/2003)
4.	Struijk, Dirk G: 14 articles (05/2015 - 01/2007)
5.	Nakayama, Masaaki: 14 articles (01/2015 - 01/2002)
6.	Nishino, Tomoya: 13 articles (05/2015 - 09/2003)
7.	Koji, Takehiko: 13 articles (05/2015 - 01/2003)
8.	Braun, Niko: 13 articles (07/2014 - 03/2007)
9.	Liu, Hong: 13 articles (07/2014 - 10/2004)
10.	Korte, Mario R: 12 articles (09/2015 - 08/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Peritoneal Fibrosis:

1.	chlorhexidine gluconate (Dyna-Hex)FDA LinkGeneric 01/01/2012 - "In this study, we investigated the role of lymphocytes in the development of peritoneal fibrosis induced by chlorhexidine gluconate (CG) by comparing the histological changes observed in severe combined immunodeficient (SCID) mice (largely lacking functional T and B lymphocytes) with those observed in wild-type (WT) mice. " 01/01/2012 - "To study this, we used microarray analysis and compared gene expression profiles of the peritoneum in control and chlorhexidine gluconate (CG)-induced peritoneal fibrosis mice. " 02/14/2009 - "The aim of the present study was to evaluate the effect of EPO on the development of experimental peritoneal fibrosis induced by chlorhexidine gluconate (CG). " 10/01/2007 - "The objective of the present study was to investigate the effect of matrix metalloproteinase inhibitor (ONO-4817), an anticancer agent with anti-angiogenesis and anti-infiltration effects, on the development of peritoneal fibrosis in chlorhexidine gluconate-induced PS rats. " 05/01/2015 - "Peritoneal fibrosis was induced by the injection of chlorhexidine gluconate (CG) into the peritoneal cavity of mice every other day for 3 weeks. "
2.	Glucose (Dextrose)FDA LinkGeneric 09/01/2014 - "In this study, we examined the therapeutic potential for miR-29b on PD-related peritoneal fibrosis in a mouse model of PD induced by daily infusion of 4.25% dextrose-containing PD fluid (PDF). " 08/01/2013 - "In the present study, we investigate the possible role of CIP4 in EMT of PMC under high glucose (HG) condition in vitro and further explore the potential therapeutic point for peritoneal fibrosis. " 02/01/2005 - "The role of glucose in determining peritoneal sclerosis is supported by morphological studies and therefore backed by much biochemical and immunological data." 01/01/2015 - "We developed a model of peritoneal fibrosis by intraperitoneally injecting 4.25%-glucose PD fluids and lipopolysaccharide to Sprague-Dawley rats. " 07/01/2012 - "Characterization of infiltrating macrophages in high glucose-induced peritoneal fibrosis in rats."
3.	Tamoxifen FDA LinkGeneric 02/01/2011 - "Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study." 01/01/2003 - "Our purpose in the present study was to investigate whether treatment with tamoxifen in PD patients with peritoneal sclerosis has a beneficial effect. " 05/01/2009 - "Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences." 01/01/2007 - "First use of tamoxifen in an HIV patient with encapsulating peritoneal sclerosis." 03/01/2006 - "Clinical experience with tamoxifen in encapsulating peritoneal sclerosis."
4.	Small Interfering RNA (siRNA)IBA 04/01/2015 - "TGF-β₁-siRNA delivery with nanoparticles inhibits peritoneal fibrosis." 07/01/2012 - "Therefore, we suggest that this controlled-release technology using HSP47 siRNA is a potential treatment for peritoneal fibrosis. " 02/01/2006 - "These results suggest the possible application of TGF-beta(1)-specific shRNA in preventing peritoneal fibrosis in patients receiving peritoneal dialysis." 01/01/2005 - "These results suggest the possible application of pcDU6 plasmid vector-mediated shRNA in preventing peritoneal fibrosis in patients receiving peritoneal dialysis." 07/01/2012 - "In the present study, we evaluated the efficacy of HSP47 small interfering RNA (siRNA) to suppress the development of peritoneal fibrosis induced by chlorhexidine gluconate in mice. "
5.	Plasminogen Activator Inhibitor 1IBA 05/01/2015 - "This study focuses on effluent MMP-2 and PAI-1 as early diagnostic markers in the preceding years of patients who develop encapsulating peritoneal sclerosis (EPS). " 05/01/2015 - "Therefore, effluent PAI-1 may aid in monitoring peritoneal fibrosis and serve as a biomarker for EPS." 05/01/2015 - "Peritoneal effluent MMP-2 and PAI-1 in encapsulating peritoneal sclerosis." 05/01/2015 - "Elevated levels of PAI-1 appearance rates are present in patients who develop EPS, pointing to progressive peritoneal fibrosis and sclerosis. " 08/01/2006 - "Increase of TGF-beta(1), CTGF, FN and PAI-1 of HPMCs stimulated by high glucose can promote the synthesis and decreased degradation of extracellular matrix, which might be related with the mechanism of peritoneal fibrosis of peritoneal mesothelial cells by high glucose."
6.	PPAR gammaIBA 12/01/2006 - "These studies suggest that the PPAR-gamma agonists may have a specific role in ameliorating the course of progressive peritoneal fibrosis under long-term peritoneal dialysis states." 06/01/2007 - "PPAR-gamma agonists may have a specific role in ameliorating the course of progressive peritoneal fibrosis under long-term peritoneal dialysis states." 01/01/2006 - "It suggested that PPARgamma might play a part in the local defense of the peritoneal cavity by downregulating inflammatory mediators, which may play a potential role in preventing peritoneal fibrosis induced by peritonitis. " 03/01/2009 - "We demonstrated the key role of transforming growth factor-beta1 (TGF-beta1), connective tissue growth factor (CTGF) and peroxisome proliferative activated receptor-gamma (PPAR-gamma) in the pathogenesis of peritoneal fibrosis, as well as their regulation of molecular mechanism. " 04/01/2009 - "The aim of this study was to demonstrate the efficacy of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist, rosiglitazone, in the amelioration or prevention of inflammation including peritoneal fibrosis secondary to the peritonitis in a peritoneal dialysis (PD) model of non-uraemic rats. "
7.	Prednisolone (Predate)FDA LinkGeneric 07/01/2008 - "These findings lead to a diagnosis of peritoneal fibrosis, and an administration of 50 mg/day of prednisolone alleviated all the symptoms. " 01/01/2000 - "Furthermore, we examined the effects of treatment with prednisolone (PSL) in a rat model of peritoneal sclerosis. " 05/01/2005 - "Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone." 01/01/2001 - "This study aimed to clarify the role of laminin (a component of the extracellular matrix) in the mechanism of peritoneal fibrosis in continuous ambulatory peritoneal dialysis (CAPD) patients, and the effect of prednisolone on such fibrosis. " 02/01/2006 - "Our results indicate that glucose induces MCP-1 mainly through hyperosmolarity by activating PKC and its downstream NF-kappaB, and that such effect was inhibited by prednisolone, suggesting the efficacy of prednisolone in preventing peritoneal fibrosis in patients on CAPD."
8.	rosiglitazone (Avandia)FDA Link 01/01/2008 - "Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model." 04/01/2009 - "The aim of this study was to demonstrate the efficacy of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist, rosiglitazone, in the amelioration or prevention of inflammation including peritoneal fibrosis secondary to the peritonitis in a peritoneal dialysis (PD) model of non-uraemic rats. " 11/01/2007 - "As no data on the potential role of these commonly used drugs in reducing peritoneal fibrosis exist, we examined the in vitro effects of an ARB (losartan) and a PPAR-gamma agonist (rosiglitazone) on inflammatory and profibrotic pathways in cultured HPMCs subjected to high glucose. "
9.	rho-Associated KinasesIBA 08/01/2013 - "The present study investigated whether Rho-kinase inhibition had a therapeutic role on the pathogenesis of peritoneal fibrosis and angiogenesis. " 08/01/2013 - "Inhibition of Rho-kinase alleviates peritoneal fibrosis and angiogenesis in a rat model of peritoneal dialysis." 09/01/2011 - "Rho-kinase inhibition ameliorates peritoneal fibrosis and angiogenesis in a rat model of peritoneal sclerosis." 08/01/2013 - "The Rho-kinase was activated in the peritoneum of the peritoneal dialysis rats, and the inhibition of Rho-kinase by fasudil can remarkably decrease peritoneal fibrosis and angiogenesis."
10.	Vitamin D FDA LinkGeneric 03/01/2013 - "The aim of the present study was to evaluate the protective effects of vitamin D against the progression of peritoneal fibrosis. " 03/01/2013 - "Our results indicate that OCT attenuates peritoneal fibrosis, an effect accompanied by reduced numbers of myofibroblasts, infiltrating macrophages, and TGF-β-positive cells, suggesting that vitamin D has potential as a novel therapeutic agent for preventing peritoneal sclerosis." 01/01/2015 - "Vitamin D Can Ameliorate Chlorhexidine Gluconate-Induced Peritoneal Fibrosis and Functional Deterioration through the Inhibition of Epithelial-to-Mesenchymal Transition of Mesothelial Cells."

Therapies and Procedures

1.	Peritoneal Dialysis 06/01/2015 - "Peritoneal dialysis (PD) is an effective treatment for patients with end-stage renal diseases, but long-term continuous PD causes peritoneal fibrosis (PF). " 01/01/2002 - "Although encapsulating peritoneal sclerosis (EPS) is feared as a fatal complication of peritoneal dialysis (PD), several recent studies have reported that many cases of EPS can be completely cured by appropriate methods of prevention and treatment. " 02/01/2014 - "Risk factors for encapsulating peritoneal sclerosis in long-term peritoneal dialysis: a retrospective observational study." 06/01/2012 - "Proof-of-principle study to detect metabolic changes in peritoneal dialysis effluent in patients who develop encapsulating peritoneal sclerosis." 05/01/2010 - "Our study shows that encapsulating peritoneal sclerosis is a rare condition, predicted by younger age and the duration of peritoneal dialysis. "
2.	Continuous Ambulatory Peritoneal Dialysis (CAPD) 07/01/2010 - "Radiologic imaging may be helpful in the early diagnosis of encapsulating peritoneal sclerosis and in facilitating timely intervention for CAPD patients with encapsulating peritoneal sclerosis." 08/01/2014 - "Peritoneal fibrosis is a complication of patients with long-term continuous ambulatory peritoneal dialysis (CAPD). " 08/01/2014 - "Peritoneal fibrosis is a major cause of ultrafiltration failure in patients receiving continuous ambulatory peritoneal dialysis. " 05/01/2012 - "Encapsulating peritoneal sclerosis (EPS) is a rare but serious complication seen in patients undergoing continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysisAPD after prolonged duration on dialysis. " 03/01/2012 - "Peritoneal fibrosis is a major complication of continuous ambulatory peritoneal dialysis (CAPD). "
3.	Transplants (Transplant) 09/01/2009 - "Encapsulating peritoneal sclerosis occurred at 3 months and 4 months after the transplant. " 03/01/1997 - "Peritoneal sclerosis is a complication of long-duration PD and could also become manifest after a successful renal transplant. " 07/01/2015 - "Switching treatment modality may potentially lead to an under-reporting of encapsulating peritoneal sclerosis, as many countries which collect data on dialysis patients in national registries often have separate registries for dialysis and transplant patients, and this may potentially lead to under-reporting of encapsulating peritoneal sclerosis in patients presenting after renal transplantation. " 09/01/2014 - "Encapsulating peritoneal sclerosis is a serious complication of peritoneal dialysis and can occur even after transplant. " 12/01/2015 - "We analyzed 3 renal transplant patients with symptoms of encapsulating peritoneal sclerosis admitted posttransplant to our hospital with ileus between 2012 and 2013. "
4.	Microbubbles 10/01/2007 - "In rats transfected with a Smad7 transgene using an ultrasound-microbubble-mediated system, peritoneal fibrosis was attenuated, peritoneal function was improved, and Smad2/3 activation was inhibited. " 01/01/2009 - "After peritoneal fibrosis had been established on day 14, groups of 6 rats were treated intraperitoneally with gene transfer of Smad7 or control plasmids using an ultrasound-microbubble-mediated system for 2 weeks until day 28. " 12/01/2007 - "In a model of peritoneal fibrosis, we tested the effect of Smad7, an inhibitor of TGF-beta signaling, using an ultrasound-microbubble-mediated delivery system. "
5.	Intraperitoneal Injections 11/01/2008 - "Previous studies have created peritoneal sclerosis rat models using daily intraperitoneal injection of chlorhexidine gluconate (CG), but this technique is cumbersome and thickening of the peritoneum makes it difficult to evaluate the injection site. " 11/01/2014 - "Rats were given a daily intraperitoneal injection of chlorhexidine gluconate (CG) for 3 weeks to induce peritoneal fibrosis. " 02/01/2007 - "Male ICR mice received intraperitoneal injections of chlorhexidine gluconate (CG) every other day to induce peritoneal sclerosis. " 03/01/1992 - "Intraperitoneal injection of zymosan induces a peritoneal inflammation, characterised by exudate in the peritoneum and peritoneal fibrosis. " 04/30/2013 - "In this study, we investigated the effect of leptin on the progression of peritoneal fibrosis induced by intraperitoneal injection of chlorhexidine gluconate (CG) every other day for 2 or 3 weeks in mice. "